TSTD2 and cerebral infarction: The present study examines the use of the anti-thiosulfate sulfurtransferase-like domain-containing 2 (TSTD2) autoantibody as a novel biomarker for atherosclerosis-related cerebral infarction and CKD in the sera of patients with atherosclerosis.